4.7 Review

Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases

Journal

CLINICAL IMMUNOLOGY
Volume 163, Issue -, Pages 52-59

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2015.12.012

Keywords

CD100/SEMA4D; Biomarker; Immunoregulator; Soluble CD100/soluble SEMA4D; Autoimmunity; Immunotherapy

Categories

Funding

  1. Karolinska Institutet
  2. Swedish Research Council
  3. Swedish Cancer Society
  4. Swedish Society for Medical Research
  5. Cancer Research Foundation's of Radiumhemmet
  6. Swedish Society of Medicine
  7. Novo Nordisk Foundation
  8. Ake Olsson's Foundation
  9. Bengt Ihre's Foundation
  10. Magnus Bergwall's Foundation
  11. Julin's Foundation
  12. Stiftelsen Professor Nanna Svartz Fond

Ask authors/readers for more resources

SEMA4D/CD100 is a homodimeric protein belonging to the semaphorin family of axonal guidance proteins. Semaphorin family members have received increased attention lately due to their diverse functions in the immune system. SEMA4D was the first semaphorin described to have immune functions and serves important roles in T cell priming, antibody production, and cell-to-cell adhesion. Proteolytic cleavage of SEMA4D from the cell surface gives rise to a soluble fragment of SEMA4D (sSEMA4D). Similar to the transmembranal form, sSEMA4D is thought to have immunoregulatory properties. While the exact mechanisms responsible for SEMA4D shedding remain to be elucidated, emerging data have revealed associations between elevated systemic sSEMA4D levels and severity of infectious and inflammatory diseases. This review summarizes the literature concerning sSEMA4D and discusses its potential as a novel prognostic immune-biomarker and potential target for immunotherapy. (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available